X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-03-10 | MNKD | Mannkind Corp | Castagna Michael | CEO | P - Purchase | $2.59 | +100,000 | 2,577,411 | +4% | +$259,000 | ||||||
| D | 2026-03-06 | NAMS | Newamsterdam Pharma Co N.V. | Lange Louis G | Dir | S - Sale+OE | $29.41 | -28,186 | 54,979 | -34% | -$828,950 | |||||
| D | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | CEO | S - Sale+OE | $3.31 | -5,100 | 44,579 | -10% | -$16,879 | |||||
| D | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Giacobello Scott M. | CFO | S - Sale+OE | $3.31 | -2,594 | 28,100 | -8% | -$8,585 | |||||
| D | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Ball Bryan | See remarks | S - Sale+OE | $3.31 | -1,834 | 206,019 | -1% | -$6,070 | |||||
| DM | 2025-08-27 | VTRS | Viatris Inc | Simmons David S | Dir | P - Purchase | $10.42 | +499 | 24,527 | +2% | +$5,202 | |||||
| D | 2026-03-09 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $16.08 | -6,693 | 451,815 | -1% | -$107,633 | |||||
2026-03-10 | VKTX | Viking Therapeutics, Inc. | Aubuchon Neil William | Chief Commercial Officer | P - Purchase | $33.50 | +4,475 | 4,475 | New | +$149,913 | ||||||
2026-03-06 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale | $29.58 | -10,000 | 51,000 | -16% | -$295,839 | ||||||
2026-03-09 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $60.72 | -2,582 | 47,858 | -5% | -$156,779 | ||||||
| D | 2026-03-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $26.84 | -2,171 | 82,489 | -3% | -$58,270 | |||||
2026-03-06 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $15.06 | +3,000 | 11,500 | +35% | +$45,180 | ||||||
2026-03-10 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $6.60 | +1,000 | 1,149,241 | 0% | +$6,599 | ||||||
| M | 2026-03-06 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $21.87 | -9,526 | 66,820 | -12% | -$208,312 | |||||
| D | 2026-03-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $518.03 | -9,500 | 639,489 | -1% | -$4,921,275 | |||||
| D | 2026-03-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $477.67 | -9,500 | 639,489 | -1% | -$4,537,853 | |||||
| D | 2026-03-06 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $98.99 | -30,000 | 324,879 | -8% | -$2,969,551 | |||||
| D | 2026-03-09 | SUPN | Supernus Pharmaceuticals, Inc. | Mottola Frank | SVP, Chief Tech. Ops. Officer | S - Sale+OE | $53.65 | -1,623 | 18,440 | -8% | -$87,074 | |||||
| DM | 2026-03-09 | SUPN | Supernus Pharmaceuticals, Inc. | Horich William Todd | SVP, Commercial Operations | S - Sale+OE | $54.50 | -8,877 | 0 | -100% | -$483,797 | |||||
| M | 2026-03-06 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $74.19 | -5,723 | 94,471 | -6% | -$424,617 | |||||
| DM | 2026-03-06 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $19.22 | -100,000 | 964,161 | -9% | -$1,922,400 | |||||
| M | 2026-03-06 | ANIP | Ani Pharmaceuticals Inc | Davis Krista | SVP, CHRO | S - Sale | $74.33 | -6,572 | 51,946 | -11% | -$488,474 | |||||
| DM | 2026-03-05 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale+OE | $30.30 | -300,000 | 69,302 | -81% | -$9,090,868 | |||||
2026-03-05 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $64.19 | -10,000 | 236,958 | -4% | -$641,900 | ||||||
| A | 2025-03-04 | BHVN | Biohaven Ltd. | Childs John W | Dir | P - Purchase | $30.43 | +28,400 | 2,397,141 | +1% | +$864,115 | |||||
2026-03-05 | PTCT | Ptc Therapeutics, Inc. | Okey Stephanie | Dir | S - Sale | $63.38 | -6,333 | 8,000 | -44% | -$401,386 | ||||||
2026-03-05 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $63.38 | -10,000 | 79,944 | -11% | -$633,800 | ||||||
2026-03-05 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $63.38 | -3,989 | 114,877 | -3% | -$252,823 | ||||||
2026-03-09 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale | $182.94 | -1,287 | 6,512 | -17% | -$235,444 | ||||||
2026-03-06 | UTHR | United Therapeutics Corp | Olian Judy D. | Dir | S - Sale | $510.00 | -200 | 4,645 | -4% | -$102,000 | ||||||
2026-03-06 | LYEL | Lyell Immunopharma, Inc. | Arch Venture Partners Ix, LLC | 10% | P - Purchase | $25.61 | +488,090 | 3,247,162 | +18% | +$12,499,985 | ||||||
| D | 2026-03-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $484.55 | -9,500 | 639,489 | -1% | -$4,603,232 | |||||
2026-03-06 | LYEL | Lyell Immunopharma, Inc. | Arch Venture Fund Xiii, L.P. | 10% | P - Purchase | $25.61 | +488,090 | 3,247,162 | +18% | +$12,499,985 | ||||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale+OE | $31.67 | -20,025 | 1,170,639 | -2% | -$634,160 | |||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, U.S. Commercial | S - Sale+OE | $31.67 | -7,924 | 84,905 | -9% | -$250,940 | |||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "Remarks" | S - Sale+OE | $31.67 | -9,533 | 107,711 | -8% | -$301,895 | |||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $31.67 | -17,295 | 85,755 | -17% | -$547,705 | |||||
| D | 2026-03-05 | AGIO | Agios Pharmaceuticals, Inc. | Viswanadhan Krishnan | Chief Corp Dev, Strategy | S - Sale+OE | $27.80 | -2,959 | 5,141 | -37% | -$82,260 | |||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Jover Placid | See "Remarks" | S - Sale+OE | $31.67 | -14,150 | 6,774 | -68% | -$448,108 | |||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Savage Brian | Interim GC | S - Sale+OE | $31.67 | -1,127 | 10,914 | -9% | -$35,690 | |||||
2026-03-05 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | COO | S - Sale | $28.93 | -2,014 | 169,914 | -1% | -$58,265 | ||||||
| M | 2026-03-05 | XNCR | Xencor Inc | Desjarlais John R | SVP, CSO | S - Sale | $11.16 | -6,620 | 263,831 | -2% | -$73,880 | |||||
| DM | 2026-03-05 | SUPN | Supernus Pharmaceuticals, Inc. | Gemayel Georges | Dir | S - Sale+OE | $53.38 | -18,787 | 27,277 | -41% | -$1,002,811 | |||||
| M | 2026-03-05 | XNCR | Xencor Inc | Eckert Celia | SVP, GC | S - Sale | $11.17 | -5,011 | 76,918 | -6% | -$55,952 | |||||
2026-03-05 | XNCR | Xencor Inc | Cornelissen Bart Jan | SVP, CFO | S - Sale | $11.25 | -2,517 | 79,397 | -3% | -$28,305 | ||||||
| M | 2026-03-05 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale | $11.18 | -21,476 | 546,316 | -4% | -$240,017 | |||||
| D | 2026-03-05 | TEVA | Teva Pharmaceutical Industries Ltd | Shields Matthew | EVP, Global Operations | S - Sale+OE | $31.67 | -17,295 | 9,989 | -63% | -$547,705 | |||||
2026-03-06 | ARVN | Arvinas, Inc. | Morrison Briggs | Dir | P - Purchase | $13.40 | +20,000 | 96,021 | +26% | +$268,070 | ||||||
2026-03-05 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale | $15.00 | -20,251 | 112,622 | -15% | -$303,765 | ||||||
2026-03-06 | ALT | Altimmune, Inc. | Weaver Gregory L | CFO | P - Purchase | $3.54 | +5,000 | 28,078 | +22% | +$17,700 | ||||||
2026-03-06 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Pres, CEO | P - Purchase | $3.54 | +20,000 | 32,500 | +160% | +$70,790 | ||||||
| DM | 2026-03-04 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $18.74 | -8,234 | 339,392 | -2% | -$154,325 | |||||
| D | 2026-03-06 | MDGL | Madrigal Pharmaceuticals, Inc. | Dier Mardi | EVP, CFO | S - Sale+OE | $430.87 | -1,982 | 12,490 | -14% | -$853,993 | |||||
| D | 2026-03-05 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | GC | S - Sale+OE | $33.86 | -10,250 | 0 | -100% | -$347,019 | |||||
| D | 2026-03-04 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale+OE | $206.35 | -5,000 | 36,869 | -12% | -$1,031,770 | |||||
| D | 2026-03-04 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $205.83 | -13,423 | 21,662 | -38% | -$2,762,822 | |||||
| D | 2026-03-06 | MDGL | Madrigal Pharmaceuticals, Inc. | Sibold William John | Pres, CEO | S - Sale+OE | $431.94 | -1,663 | 161,829 | -1% | -$718,316 | |||||
| D | 2026-03-06 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale+OE | $431.94 | -360 | 12,138 | -3% | -$155,498 | |||||
| D | 2026-03-06 | MDGL | Madrigal Pharmaceuticals, Inc. | Huntsman Carole | Chief Commercial Officer | S - Sale+OE | $431.94 | -419 | 12,692 | -3% | -$180,983 | |||||
2026-03-06 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale | $431.94 | -491 | 1,107,753 | 0% | -$212,083 | ||||||
| M | 2026-03-05 | SDGR | Schrodinger, Inc. | Herman Jenny | CAO | S - Sale | $12.84 | -1,383 | 34,804 | -4% | -$17,764 | |||||
2026-03-05 | SDGR | Schrodinger, Inc. | Jain Rachit | EVP, CFO | S - Sale | $12.90 | -1,631 | 52,596 | -3% | -$21,033 | ||||||
2026-03-05 | SDGR | Schrodinger, Inc. | Tran Yvonne | EVP, CLO, CPO | S - Sale | $12.90 | -1,094 | 52,683 | -2% | -$14,107 | ||||||
2026-03-05 | SDGR | Schrodinger, Inc. | Farid Ramy | Pres, CEO | S - Sale | $12.91 | -3,661 | 330,824 | -1% | -$47,249 | ||||||
2026-03-05 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale | $12.90 | -1,366 | 69,956 | -2% | -$17,625 | ||||||
2026-03-05 | SDGR | Schrodinger, Inc. | Lorton Kenneth Patrick | EVP, CTO, COO, Software | S - Sale | $12.90 | -1,222 | 89,241 | -1% | -$15,761 | ||||||
2026-03-04 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | See Remarks | S - Sale | $12.81 | -1,300 | 55,897 | -2% | -$16,653 | ||||||
| D | 2026-03-04 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, MD | S - Sale+OE | $9.06 | -14,581 | 660,658 | -2% | -$132,104 | |||||
2026-03-04 | ABBV | Abbvie Inc. | Purdue David Ryan | SVP, Controller | S - Sale | $233.56 | -5,230 | 3,197 | -62% | -$1,221,519 | ||||||
2026-03-05 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $3.90 | +10,000 | 1,148,241 | +1% | +$39,000 | ||||||
| D | 2026-03-04 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale+OE | $9.06 | -808 | 189,669 | 0% | -$7,320 | |||||
| D | 2026-03-04 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $64.87 | -64,921 | 18,589 | -78% | -$4,211,302 | |||||
2026-03-04 | GENB | Generate Biomedicines, Inc. | Nally Michael | CEO | P - Purchase | $12.00 | +20,000 | 2,889,154 | +1% | +$240,000 | ||||||
| D | 2026-03-04 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $89.56 | -5,614 | 160 | -97% | -$502,790 | |||||
2026-03-04 | TRDA | Entrada Therapeutics, Inc. | Wentworth Kory James | CFO | S - Sale | $12.25 | -7,988 | 137,987 | -5% | -$97,892 | ||||||
| D | 2026-03-04 | QURE | Uniqure N.V. | Potts Jeannette | GC | S - Sale+OE | $9.06 | -3,412 | 138,483 | -2% | -$30,913 | |||||
| D | 2026-03-04 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $35.99 | -8,233 | 2,231 | -79% | -$296,346 | |||||
| D | 2026-03-04 | QURE | Uniqure N.V. | Klemt Christian | CFO | S - Sale+OE | $9.06 | -12,000 | 226,581 | -5% | -$108,720 | |||||
2026-03-05 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $19.06 | -15,569 | 3,517 | -82% | -$296,745 | ||||||
| DM | 2026-03-04 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $19.19 | -100,000 | 964,161 | -9% | -$1,919,208 | |||||
| D | 2026-03-04 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale+OE | $32.46 | -23,393 | 1,148,212 | -2% | -$759,442 | |||||
| D | 2026-03-04 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $32.66 | -91,345 | 85,755 | -52% | -$2,983,517 | |||||
2026-03-04 | PEPG | Pepgen Inc. | Streck Paul | EVP, Head of R, D | S - Sale | $6.23 | -1,879 | 76,226 | -2% | -$11,709 | ||||||
| M | 2026-03-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $323.53 | -4,713 | 19,374 | -20% | -$1,524,796 | |||||
2026-03-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $323.08 | -2,933 | 96,102 | -3% | -$947,581 | ||||||
2026-03-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $323.08 | -2,468 | 61,862 | -4% | -$797,351 | ||||||
2026-03-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $323.08 | -2,309 | 34,297 | -6% | -$745,984 | ||||||
2026-03-04 | PEPG | Pepgen Inc. | Donnelly Noel | CFO | S - Sale | $6.23 | -2,084 | 111,603 | -2% | -$12,988 | ||||||
| M | 2026-03-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $323.54 | -1,291 | 21,106 | -6% | -$417,685 | |||||
2026-03-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $14.90 | -148 | 154,581 | 0% | -$2,205 | ||||||
| D | 2026-03-04 | TEVA | Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "Remarks" | S - Sale+OE | $32.46 | -11,277 | 97,590 | -10% | -$366,102 | |||||
2026-03-04 | PEPG | Pepgen Inc. | McArthur James G | Pres, CEO | S - Sale | $6.23 | -5,275 | 296,326 | -2% | -$32,876 | ||||||
2026-03-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $14.90 | -904 | 171,606 | -1% | -$13,470 | ||||||
2026-03-05 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $14.90 | -2,732 | 446,145 | -1% | -$40,707 | ||||||
| D | 2026-03-04 | TEVA | Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, U.S. Commercial | S - Sale+OE | $32.46 | -9,098 | 75,010 | -11% | -$295,362 | |||||
2026-03-04 | VRTX | Vertex Pharmaceuticals Inc / Ma | McKechnie Duncan | EVP, Chief Commercial Officer | S - Sale | $475.30 | -2,437 | 15,122 | -14% | -$1,158,306 | ||||||
| D | 2026-03-04 | TEVA | Teva Pharmaceutical Industries Ltd | Savage Brian | Interim GC | S - Sale+OE | $32.46 | -2,675 | 8,461 | -24% | -$86,843 | |||||
| D | 2026-03-04 | ERAS | Erasca, Inc. | Morris Shannon | Chief Medical Officer | S - Sale+OE | $15.04 | -20,000 | 0 | -100% | -$300,760 | |||||
2026-03-05 | PMN | Promis Neurosciences Inc. | Williams Eugene | Dir | P - Purchase | $24.40 | +2,000 | 12,397 | +19% | +$48,800 | ||||||
| DM | 2026-03-03 | OLMA | Olema Pharmaceuticals, Inc. | Mitchell Shawnte | GC | S - Sale+OE | $23.79 | -40,000 | 233 | -99% | -$951,503 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |